Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
5.11
-0.03 (-0.68%)
Aug 15, 2025, 9:42 AM - Market open
Evoke Pharma Revenue
Evoke Pharma had revenue of $3.75M in the quarter ending June 30, 2025, with 47.06% growth. This brings the company's revenue in the last twelve months to $12.79M, up 70.02% year-over-year. In the year 2024, Evoke Pharma had annual revenue of $10.25M with 97.84% growth.
Revenue (ttm)
$12.79M
Revenue Growth
+70.02%
P/S Ratio
0.60
Revenue / Employee
$4,264,953
Employees
3
Market Cap
10.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.25M | 5.07M | 97.84% |
Dec 31, 2023 | 5.18M | 2.67M | 106.51% |
Dec 31, 2022 | 2.51M | 890.57K | 55.04% |
Dec 31, 2021 | 1.62M | 1.60M | 6,929.00% |
Dec 31, 2020 | 23.02K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EVOK News
- 9 days ago - Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 - GlobeNewsWire
- 5 weeks ago - Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 - GlobeNewsWire
- 3 months ago - Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 - GlobeNewsWire
- 5 months ago - Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 - GlobeNewsWire
- 6 months ago - Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - GlobeNewsWire